Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ciprofloxacin
Drug ID BADD_D00471
Description Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
Indications and Usage Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478] A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493] A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475] A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]
Marketing Status approved; investigational
ATC Code J01MA02; S01AE03; S02AA15; S03AA07
DrugBank ID DB00537
KEGG ID D00186
MeSH ID D002939
PubChem ID 2764
TTD Drug ID D0O1WX
NDC Product Code 72789-118; 82982-025; 42708-146; 67296-1848; 0409-2300; 70518-3063; 70985-008; 71610-081; 76420-214; 12527-0537; 16252-516; 52286-0014; 16571-412; 50090-5483; 55111-126; 60429-042; 61919-795; 62135-392; 68071-1893; 68071-2913; 69315-308; 71335-2097; 72189-300; 0615-8367; 72789-193; 53069-0680; 36000-297; 0143-9929; 45865-471; 50090-4220; 55111-125; 62135-393; 63187-001; 66992-450; 67296-1269; 68071-2525; 68788-7905; 68788-9012; 70985-011; 71335-1867; 71335-2054; 63187-017; 63629-7786; 66267-919; 68788-7500; 71205-749; 71335-1640; 0904-7083; 16252-514; 36000-009; 0143-9927; 55154-3368; 55700-737; 58657-676; 63629-1724; 63629-5154; 67296-1097; 67296-1389; 67296-1479; 68071-3013; 68788-9006; 70518-2390; 72789-124; 0904-7243; 42708-088; 45865-530; 53002-2642; 53002-2790; 55111-128; 58657-675; 63629-1326; 67296-1575; 0409-3300; 0409-4777; 70518-0693; 70934-316; 72789-125; 16571-413; 45865-772; 53002-2640; 63629-3868; 67296-0237; 67296-1318; 68788-8200; 72189-242; 80425-0164; 55111-015; 25021-192; 35356-733; 0143-9928; 50090-4217; 61919-371; 63187-990; 68071-4201; 0904-6378; 58032-0127; 16571-411; 25021-114; 36000-008; 43063-547; 43063-767; 51655-086; 54348-662; 54348-663; 55111-127; 60760-815; 61919-361; 63187-142; 63629-7950; 68788-9280; 70518-2837; 70985-012; 71335-1393; 16252-515; 42195-550; 43063-410; 43063-869; 60760-676; 68071-2267; 68071-2269; 68788-7864; 68788-9024; 70518-3417; 71205-300; 71335-0070; 71335-0408; 72189-304; 72189-323; 72789-108; 12527-0540; 36000-298; 42708-002; 45865-994; 50090-5621; 50419-773; 50419-777; 51655-118; 51655-490; 53002-2791
UNII 5E8K9I0O4U
Synonyms Ciprofloxacin | Ciprofloxacin Hydrochloride Anhydrous | Anhydrous, Ciprofloxacin Hydrochloride | Hydrochloride Anhydrous, Ciprofloxacin | Cipro | Ciprofloxacin Hydrochloride | Hydrochloride, Ciprofloxacin | Ciprofloxacin Monohydrochloride Monohydrate | Monohydrate, Ciprofloxacin Monohydrochloride | Monohydrochloride Monohydrate, Ciprofloxacin | Bay-09867 | Bay 09867 | Bay09867 | Ciprinol
Chemical Information
Molecular Formula C17H18FN3O3
CAS Registry Number 85721-33-1
SMILES C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Superinfection11.01.08.009--Not Available
Surgery25.01.02.003--Not Available
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Swollen tongue10.01.05.015; 07.14.02.003; 23.04.01.014--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.0080.000021%
Tachycardia02.03.02.007--Not Available
Tachypnoea22.02.01.014--Not Available
Tenderness08.01.08.005--Not Available
Tendon disorder12.01.07.019; 15.07.01.002--Not Available
Tendon rupture12.01.07.003; 15.07.01.008--Not Available
Tendonitis15.07.01.003; 12.01.07.0070.000069%Not Available
Tension19.06.02.005--Not Available
Therapeutic response decreased08.06.01.0160.000021%Not Available
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Throat tightness22.12.03.031; 19.01.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000021%
Tongue discolouration07.14.02.006--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tooth discolouration07.09.02.001--
Toothache07.09.06.001--
Torsade de pointes02.03.04.005--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tremor17.01.06.0020.000021%
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene